Metastatic Melanoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Metastatic Melanoma - Pipeline Review, H1 2012, provides an overview of the Metastatic Melanoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. Metastatic Melanoma - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Melanoma.
- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Metastatic Melanoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Melanoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Metastatic Melanoma 11
Metastatic Melanoma Therapeutics under Development by Companies 13
Metastatic Melanoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Metastatic Melanoma Therapeutics – Products under Development by Companies 28
Metastatic Melanoma Therapeutics – Products under Investigation by Universities/Institutes 32
Companies Involved in Metastatic Melanoma Therapeutics Development 44
Bristol-Myers Squibb Company 44
F. Hoffmann-La Roche Ltd. 45
Abbott Laboratories 46
Vical Incorporated 47
Adherex Technologies Inc. 48
Viralytics Ltd. 49
GlaxoSmithKline plc 50
Genentech, Inc. 51
MedImmune LLC 52
Emergent BioSolutions Inc. 53
Millennium Pharmaceuticals, Inc. 54
Novartis AG 55
ImClone Systems Incorporated 56
Pain Therapeutics, Inc. 57
Celgene Corporation 58
3SBio Inc. 59
EpiCept Corporation 60
Celldex Therapeutics, Inc. 61
Molecular Insight Pharmaceuticals, Inc. 62
Northwest Biotherapeutics, Inc. 63
Osta Biotechnologies Inc. 64
Advanced Life Sciences Holdings, Inc. 65
Progen Pharmaceuticals Limited 66
Threshold Pharmaceuticals, Inc. 67
Provectus Pharmaceuticals, Inc. 68
BioAlliance Pharma SA 69
Piramal Life Sciences Limited 70
Morphotek, Inc. 71
Antisense Pharma GmbH 72
Philogen S.p.A. 73
Curacyte AG 74
Cytheris SA 75
Altor BioScience Corporation 76
Affichem 77
Myriad Pharmaceuticals, Inc. 78
Omeros Corporation 79
Immunocore Limited. 80
CureTech Ltd. 81
Medisyn Technologies, Inc. 82
Cytavis Biopharma GmbH 83
Gradalis Inc. 84
Lipotek Pty Ltd 85
Metastatic Melanoma – Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Combination Products 87
Assessment by Route of Administration 88
Assessment by Molecule Type 91
Drug Profiles 94
GSK1120212 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Allovectin-7 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Zelboraf - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Abraxane - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
NuLeusin - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Aldesleukin + Vaccine Therapy - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
GP100 Antigen + Incomplete Freunds adjuvant + Aldesleukin - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Aldesleukin + Ceplene - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
MDX-010 + DTIC - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Aldesleukin + Gp100 Antigen + Incomplete Freunds Adjuvant - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 107
MART-1 Antigen + GP-100 Antigen + Tyrosinase Peptide + GM-CSF + Incomplete Freunds Adjuvant - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
GSK2118436 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Interleukin-2 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Metastatic Melanoma Therapeutics – Drug Profile Updates 113
Metastatic Melanoma Therapeutics – Discontinued Products 118
Metastatic Melanoma Therapeutics - Dormant Products 120
Metastatic Melanoma – Product Development Milestones 133
Featured News & Press Releases 133
Dec 16, 2011: Roches Zelboraf Receives Positive Opinion From European Authority For Treatment Of People With BRAF Mutation-Positive Metastatic Melanoma 133
Nov 29, 2011: Provectus Reports On Third End-Of-Phase II Meeting With FDA To Define Pathway To Approval Of PV-10 for Metastatic Melanoma 133
Nov 22, 2011: Researchers Identify P Rex-1 Protein That Contributes To Development Of Melanoma 134
Nov 14, 2011: Provectus Presents Data On PV-10 For Metastatic Melanoma At 2011 International Melanoma Congress 134
Nov 10, 2011: Phase II Data on Provectus’s PV-10 For Metastatic Melanoma To Be Presented At 2011 International Melanoma Congress 135
Sep 13, 2011: BioAlliance Announces Positive Preliminary Phase I Clinical Results With AMEP Biotherapy For Metastatic Melanoma 135
Aug 17, 2011: Roche Announces FDA Approval For Zelboraf And Companion Diagnostic For BRAF Mutation-Positive Metastatic Melanoma 136
Aug 02, 2011: Jennerex Reports Positive Mechanistic Proof Of Concept Clinical Trial Results Using JX-594 To Treat Metastatic Melanoma 137
Jul 13, 2011: CYTAVISs Aviscumine Improves Survival Of Patients With Metastatic Melanoma In Phase II Trial 138
Jun 29, 2011: Provectus Presents Additional Data On PV-10 For Metastatic Melanoma At Prominent Melanoma Conferences 139
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 141
Contact Us 141
Disclaimer 141

List of Tables

Number of Products Under Development for Metastatic Melanoma, H1 2012 11
Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012 12
Number of Products under Development by Companies, H1 2012 14
Number of Products under Development by Companies, H1 2012 (Contd..1) 15
Number of Products under Development by Companies, H1 2012 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 23
Comparative Analysis by Late Stage Development, H1 2012 24
Comparative Analysis by Mid Clinical Stage Development, H1 2012 25
Comparative Analysis by Early Clinical Stage Development, H1 2012 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 27
Products under Development by Companies, H1 2012 28
Products under Development by Companies, H1 2012 (Contd..1) 29
Products under Development by Companies, H1 2012 (Contd..2) 30
Products under Development by Companies, H1 2012 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2012 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 43
Bristol-Myers Squibb Company, H1 2012 44
F. Hoffmann-La Roche Ltd., H1 2012 45
Abbott Laboratories, H1 2012 46
Vical Incorporated, H1 2012 47
Adherex Technologies Inc., H1 2012 48
Viralytics Ltd., H1 2012 49
GlaxoSmithKline plc, H1 2012 50
Genentech, Inc., H1 2012 51
MedImmune LLC, H1 2012 52
Emergent BioSolutions Inc., H1 2012 53
Millennium Pharmaceuticals, Inc., H1 2012 54
Novartis AG, H1 2012 55
ImClone Systems Incorporated, H1 2012 56
Pain Therapeutics, Inc., H1 2012 57
Celgene Corporation, H1 2012 58
3SBio Inc., H1 2012 59
EpiCept Corporation, H1 2012 60
Celldex Therapeutics, Inc., H1 2012 61
Molecular Insight Pharmaceuticals, Inc., H1 2012 62
Northwest Biotherapeutics, Inc., H1 2012 63
Osta Biotechnologies Inc., H1 2012 64
Advanced Life Sciences Holdings, Inc., H1 2012 65
Progen Pharmaceuticals Limited, H1 2012 66
Threshold Pharmaceuticals, Inc., H1 2012 67
Provectus Pharmaceuticals, Inc., H1 2012 68
BioAlliance Pharma SA, H1 2012 69
Piramal Life Sciences Limited, H1 2012 70
Morphotek, Inc., H1 2012 71
Antisense Pharma GmbH, H1 2012 72
Philogen S.p.A., H1 2012 73
Curacyte AG, H1 2012 74
Cytheris SA, H1 2012 75
Altor BioScience Corporation, H1 2012 76
Affichem, H1 2012 77
Myriad Pharmaceuticals, Inc., H1 2012 78
Omeros Corporation, H1 2012 79
Immunocore Limited., H1 2012 80
CureTech Ltd., H1 2012 81
Medisyn Technologies, Inc., H1 2012 82
Cytavis Biopharma GmbH, H1 2012 83
Gradalis Inc., H1 2012 84
Lipotek Pty Ltd, H1 2012 85
Assessment by Monotherapy Products, H1 2012 86
Assessment by Combination Products, H1 2012 87
Assessment by Stage and Route of Administration, H1 2012 90
Assessment by Molecule Type, H1 2012 93
Metastatic Melanoma Therapeutics – Drug Profile Updates 113
Metastatic Melanoma Therapeutics – Discontinued Products 118
Metastatic Melanoma Therapeutics – Discontinued Products (Contd..1) 119
Metastatic Melanoma Therapeutics – Dormant Products 120
Metastatic Melanoma Therapeutics – Dormant Products (Contd..1) 121
Metastatic Melanoma Therapeutics – Dormant Products (Contd..2) 122
Metastatic Melanoma Therapeutics – Dormant Products (Contd..3) 123
Metastatic Melanoma Therapeutics – Dormant Products (Contd..4) 124
Metastatic Melanoma Therapeutics – Dormant Products (Contd..5) 125
Metastatic Melanoma Therapeutics – Dormant Products (Contd..6) 126
Metastatic Melanoma Therapeutics – Dormant Products (Contd..7) 127
Metastatic Melanoma Therapeutics – Dormant Products (Contd..8) 128
Metastatic Melanoma Therapeutics – Dormant Products (Contd..9) 129
Metastatic Melanoma Therapeutics – Dormant Products (Contd..10) 130
Metastatic Melanoma Therapeutics – Dormant Products (Contd..11) 131
Metastatic Melanoma Therapeutics – Dormant Products (Contd..12) 132

List of Figures

Number of Products under Development for Metastatic Melanoma, H1 2012 11
Products under Development for Metastatic Melanoma – Comparative Analysis, H1 2012 12
Products under Development by Companies, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 17
Late Stage Products, H1 2012 24
Mid Clinical Stage Products, H1 2012 25
Early Clinical Stage Products, H1 2012 26
Discovery and Pre-Clinical Stage Products, H1 2012 27
Assessment by Monotherapy Products, H1 2012 86
Assessment by Combination Products, H1 2012 87
Assessment by Route of Administration, H1 2012 88
Assessment by Stage and Route of Administration, H1 2012 89
Assessment by Molecule Type, H1 2012 91
Assessment by Stage and Molecule Type, H1 2012 92